Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.48 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29749063 | 1.00 | KDM1A (0.48) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL30370466 | 1.00 | KDM1A (0.48) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL937009 | 1.00 | KDM1A (0.48) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL4753167 | 0.82 | KDM1A (0.43) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL7055104 | 0.82 | HTR2C (0.49) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL20833596 | 0.82 | HTR2C (0.49) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL28759921 | 0.82 | KDM1A (0.45) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL37732 | 0.82 | TSHR (0.57) | TSHRNOS3NOS2 | |
| SCHEMBL13224382 | 0.80 | CHRNB2 (0.42) | KDM1AKDM1BTSHRHTR2CHTR2B | |
| SCHEMBL11358035 | 0.80 | KDM1A (0.41) | KDM1AKDM1BTSHRHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540157-B2 | Oxysterols and methods of use thereof | Sage Therapeutics, LLC (US) | 2026-02-03 | — | — | US | disclosed |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2024-11-28 | — | — | US | disclosed |
| EP-4405041-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | Atrogi AB (SE) | 2024-07-31 | — | — | EP | disclosed |
| US-20240199682-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11851457-B2 | Oxysterols and methods of use thereof | SAGE THERAPEUTICS (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4252848-A2 | OXYSTEROLS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| US-4391826-A | DIETETICS | ELI LILLY AND COMPANY (US) | 1983-07-05 | — | — | US | disclosed |
| EP-0007206-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1983-02-23 | — | — | EP | disclosed |
| EP-0006766-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, USE AND PREPARATION | ELI LILLY AND COMPANY (US) | 1983-01-26 | — | — | EP | disclosed |
| EP-0007204-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, USE AND PREPARATION | ELI LILLY AND COMPANY (US) | 1982-11-24 | — | — | EP | disclosed |
| EP-0048037-A1 | Optically active 1-alkyl-3-(4-substituted-phenyl)-propylamines | ELI LILLY AND COMPANY (US) | 1982-03-24 | — | — | EP | disclosed |
| EP-0047536-A2 | Substituted propylamines | ELI LILLY AND COMPANY (US) | 1982-03-17 | — | — | EP | disclosed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
| EP-0007204-A1 | Phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
| EP-0007205-A1 | Optically active phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
| EP-0006766-A1 | Phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | H1-5, CYP3A5, HRH3 | KDM1A 1282/4885KDM1B 1425/4885TSHR 2693/4885 |
| US-12540157-B2 | Oxysterols and methods of use thereof | HSD3B2, HSD3B1, HSD17B7 | KDM1A 4209/4885KDM1B 4035/4885TSHR 1011/4885 |
| US-20240199682-A1 | OXYSTEROLS AND METHODS OF USE THEREOF | NR1H3, NR1H2, HSD17B7 | KDM1A 3351/4885KDM1B 3430/4885TSHR 998/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | KDM1A 1627/4885KDM1B 1528/4885TSHR 1556/4885 |
| US-11851457-B2 | Oxysterols and methods of use thereof | NR1H3, NR1H2, HSD17B7 | KDM1A 3233/4885KDM1B 3341/4885TSHR 915/4885 |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | KDM1A 1627/4885KDM1B 1528/4885TSHR 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.